Abiopharma

🔍 Liu Chang (Director)

Company: CATHAY GENERAL BANCORP (CATY)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-26 | Code: H | shares_owned_after: 127,819.00
• Acquired 9,408 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,408.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2, F2
• Acquired 8,863 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,863.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2, F2
• Acquired 17,727 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 17,727.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represented a contingent right to receive one share of Common Stock upon vesting. The number of restricted stock units that are earned can be reduced by up to 100% of the target award or increased by up to 150% of the target award, depending upon the achievement of certain performance criteria.
• F2: These restricted stock units are scheduled to vest in a single installment on December 31, 2028, subject to continued employment, but may vest to some extent earlier in the event of death, disability, retirement after December 31, 2027 or a change in control, with the number of units earned being based on the achievement of certain performance criteria.